Overview

A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)

Status:
Completed

Trial end date:
2015-11-11

Target enrollment:

Participant gender:

Summary

The purpose of this study was to assess tolerability of mirabegron compared to tolterodine ER in the treatment of participants with symptoms of Overactive Bladder (OAB) as well as the impact of treatment on micturition frequency and incontinence episodes.

Phase:

Phase 4

Details

Lead Sponsor:

Astellas Pharma Global Development, Inc.

Treatments:

Mirabegron
Tolterodine Tartrate